Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Sells $52,805.79 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) CEO Ming Hsieh sold 2,313 shares of Fulgent Genetics stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total value of $52,805.79. Following the completion of the transaction, the chief executive officer now owns 707,275 shares in the company, valued at approximately $16,147,088.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Fulgent Genetics Stock Up 1.2 %

Shares of FLGT traded up $0.27 during trading hours on Thursday, hitting $23.12. The company had a trading volume of 97,626 shares, compared to its average volume of 186,510. The firm has a market cap of $691.84 million, a P/E ratio of -4.15 and a beta of 1.37. The stock’s 50 day moving average price is $22.28 and its 200 day moving average price is $21.99. Fulgent Genetics, Inc. has a 52-week low of $18.91 and a 52-week high of $33.97.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings data on Friday, August 2nd. The company reported $0.15 EPS for the quarter, topping the consensus estimate of ($0.30) by $0.45. The firm had revenue of $71.03 million for the quarter, compared to the consensus estimate of $69.07 million. Fulgent Genetics had a negative return on equity of 2.92% and a negative net margin of 57.72%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.33) earnings per share. On average, research analysts expect that Fulgent Genetics, Inc. will post -2.12 EPS for the current fiscal year.

Institutional Trading of Fulgent Genetics

Several large investors have recently modified their holdings of FLGT. Louisiana State Employees Retirement System bought a new stake in shares of Fulgent Genetics in the fourth quarter worth about $292,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Fulgent Genetics by 34.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,569 shares of the company’s stock worth $190,000 after purchasing an additional 1,667 shares during the last quarter. Illinois Municipal Retirement Fund grew its stake in shares of Fulgent Genetics by 5.6% in the fourth quarter. Illinois Municipal Retirement Fund now owns 12,534 shares of the company’s stock worth $362,000 after purchasing an additional 668 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Fulgent Genetics by 14.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 267,313 shares of the company’s stock worth $7,728,000 after purchasing an additional 33,141 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Fulgent Genetics by 11.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,447,153 shares of the company’s stock worth $41,839,000 after purchasing an additional 147,505 shares during the last quarter. 48.06% of the stock is owned by institutional investors.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.